Abstract Number: 312 • 2014 ACR/ARHP Annual Meeting
Mutations in the MTHFR Gene Are Not Associated with Methotrexate Intolerance in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Methotrexate (MTX) is the drug used most frequently in the therapy of juvenile idiopathic arthritis (JIA). However, long-term treatment in children frequently leads…Abstract Number: 311 • 2014 ACR/ARHP Annual Meeting
Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome
Background/Purpose: MAS occurs frequently in patients with active systemic juvenile idiopathic arthritis(s-JIA) and because of the similarities with Haemophagocytic Lymphohistiocytosis (HLH) is classified among secondary…Abstract Number: 310 • 2014 ACR/ARHP Annual Meeting
Differential Expression of microRNA in Monocytes from Children with Systemic Juvenile Idiopathic Arthritis: Implications for Polarized Phenotype
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease of childhood, and the predominant effector cells are mononuclear phagocytes rather than lymphocytes as in…Abstract Number: 309 • 2014 ACR/ARHP Annual Meeting
Clinical Significance of Cytokine Profile with Interleukin-18 and -6 in Systemic Juvenile Idiopathic Arthritis
Background/Purpose Innate proinflammatory cytokines interleukin (IL)-6 and IL-18 are critical for perpetuating the inflammatory processes in systemic juvenile idiopathic arthritis (s-JIA) and macrophage activation syndrome…Abstract Number: 307 • 2014 ACR/ARHP Annual Meeting
Sibling Exposure and Risk of Juvenile Idiopathic Arthritis
Background/Purpose: Susceptibility to juvenile idiopathic arthritis (JIA) is presumed to be determined by the interplay of genes and environment. Our understanding of the genetic basis…Abstract Number: 308 • 2014 ACR/ARHP Annual Meeting
Tenascin-C, a TLR4 Ligand Levels in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis: Cross-Sectional and Longitudinal Study
Background/Purpose Tenascin-C (TNC) is an extracellular matrix glycoprotein, which binds to TLR4 and leads to its activation. Monocytes of children with Enthesitis related arthritis (ERA)…Abstract Number: 306 • 2014 ACR/ARHP Annual Meeting
Association of Kawasaki Disease with Tropospheric Winds in Central Chile: Is Wind-Borne Desert Dust a Risk Factor?
Background/Purpose: Kawasaki disease (KD) has been reported to have seasonal variations in many different countries, as well as geographical and temporal clustering. It has been…Abstract Number: 305 • 2014 ACR/ARHP Annual Meeting
Understanding the Molecular Pathogenesis of and Response to Canakinumab Treatment in TNF Receptor-Associated Periodic Syndrome By Gene Expression Profiling of Whole Blood from Patients
Background/Purpose: TNF receptor-associated periodic syndrome (TRAPS) is an autoinflammatory disease causing unprovoked fevers, myalgia, abdominal pain, rash, headaches, and, in severe cases, AA amyloidosis. It…Abstract Number: 304 • 2014 ACR/ARHP Annual Meeting
Juvenile Rheumatoid Arthritis and Future Risk for Cardiovascular Disease; A Multicenter Population-Based Study
Background/Purpose: Several studies suggest an increased frequency of cardiovascular disease (CVD) in patients with rheumatoid arthritis, but little is known about CVD risk in patients…Abstract Number: 288 • 2014 ACR/ARHP Annual Meeting
Establishing Clinical Meaning and Defining Important Differences in Patient Reported Outcome Measures of Physical Function, Fatigue and Pain Interference in Juvenile Idiopathic Arthritis
Background/Purpose Patient reported outcome measures (PROs) are used increasingly in clinical care. A framework to interpret scores according to degree of clinical severity would enhance…Abstract Number: 287 • 2014 ACR/ARHP Annual Meeting
Role of Joint Status in Decreased Accelerometer-Assessed Daily Physical Activity in Juvenile Idiopathic Arthritis
Background/Purpose Juvenile Idiopathic Arthritis (JIA) is often associated with decreased physical activity (PA). Although improved disease control has opened up the possibilities for JIA-children to…Abstract Number: 286 • 2014 ACR/ARHP Annual Meeting
Using the 2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis (JIA) to Evaluate a Single Centre Treatment Pathway: A Feasibility Study
Background/Purpose The 2011 ACR recommendations for the treatment of Juvenile Idiopathic Arthritis (ACR-JIA) are evidence-based, consensus-approved therapeutic pathways for the safe and effective treatment of…Abstract Number: 285 • 2014 ACR/ARHP Annual Meeting
Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX
Background/Purpose Drug surveillance of biologics in juvenile patients using registries is of immense importance as patient numbers and duration in clinical trials are limited. There…Abstract Number: 284 • 2014 ACR/ARHP Annual Meeting
Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE)– Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Idiopathic Arthritis
Background/Purpose Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic pediatric rheumatic diseases (PRD). As is the case for most PRD's, evidence-based guidelines…Abstract Number: 283 • 2014 ACR/ARHP Annual Meeting
Agreement Between Enthesitis Evaluation By Manual Palpation and Dolorimetry in Juvenile Spondyloarthritis
Background/Purpose: Enthesitis is a characteristic feature of spondyloarthritis (SpA). Clinical evaluation of enthesitis by palpation is subject to differences in pressure used at different sites…
ACR Meeting Abstracts